Down-regulation	O
of	O
human	O
granzyme	B-protein
B	I-protein
expression	O
by	O
glucocorticoids	O
.	O

Dexamethasone	O
inhibits	O
binding	O
to	O
the	O
Ikaros	B-protein
and	O
AP-1	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
.	O

The	O
serine	B-protein
protease	I-protein
granzyme	I-protein
B	I-protein
is	O
an	O
essential	O
component	O
of	O
the	O
granule	O
exocytosis	O
pathway	O
,	O
a	O
major	O
apoptotic	O
mechanism	O
used	O
by	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
to	O
induce	O
target	O
cell	O
apoptosis	O
.	O

Granzyme	O
B	O
gene	O
transcription	O
is	O
induced	O
in	O
activated	O
lymphocytes	B-cell_type
upon	O
antigenic	O
stimulation	O
,	O
and	O
several	O
regulatory	B-DNA
regions	I-DNA
including	O
CBF	B-protein
,	O
AP-1	B-protein
,	O
and	O
Ikaros	B-DNA
binding	I-DNA
sites	I-DNA
have	O
been	O
shown	O
to	O
be	O
essential	O
in	O
the	O
control	O
of	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
activation	O
.	O

Dexamethasone	O
,	O
a	O
glucocorticoid	O
that	O
is	O
widely	O
used	O
as	O
an	O
immunomodulatory	O
and	O
anti-inflammatory	O
agent	O
,	O
inhibits	O
granzyme	B-RNA
B	I-RNA
mRNA	I-RNA
transcript	I-RNA
in	O
phytohemagglutinin-activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Transfection	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
-148	B-DNA
to	I-DNA
+60	I-DNA
region	I-DNA
of	O
the	O
human	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
demonstrated	O
that	O
this	O
region	O
was	O
the	O
target	O
for	O
dexamethasone	O
repression	O
.	O

Mutation	O
of	O
Ikaros	B-protein
or	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
context	O
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
demonstrated	O
that	O
both	O
sites	O
participate	O
in	O
dexamethasone-mediated	O
inhibition	O
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
activity	O
.	O

Electromobility	O
shift	O
assay	O
revealed	O
that	O
dexamethasone	O
abolished	O
the	O
binding	O
of	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
to	O
the	O
Ikaros	B-DNA
binding	I-DNA
site	I-DNA
and	O
reduced	O
AP-1	B-protein
binding	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
dexamethasone	O
is	O
able	O
to	O
abrogate	O
the	O
transcriptional	O
activity	O
of	O
the	O
human	B-DNA
granzyme	I-DNA
B	I-DNA
gene	I-DNA
promoter	I-DNA
by	O
inhibiting	O
the	O
binding	O
of	O
nuclear	B-protein
factors	I-protein
at	O
the	O
AP-1	B-DNA
and	I-DNA
Ikaros	I-DNA
sites	I-DNA
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

273	NULL
,	NULL
No	NULL
.	NULL

52	NULL
,	NULL
Issue	NULL
of	NULL
December	NULL
25	NULL
,	NULL
pp	NULL
.	NULL

35326-35331	NULL
,	NULL
1998	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Down-regulation	NULL
of	NULL
Human	NULL
Granzyme	NULL
B	NULL
Expression	NULL
by	NULL
Glucocorticoids	NULL
DEXAMETHASONE	NULL
INHIBITS	NULL
BINDING	NULL
TO	NULL
THE	NULL
Ikaros	NULL
AND	NULL
AP-1	NULL
REGULATORY	NULL
ELEMENTS	NULL
OF	NULL
THE	NULL
GRANZYME	NULL
B	NULL
PROMOTER*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
November	NULL
10	NULL
,	NULL
1997	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
October	NULL
12	NULL
,	NULL
1998	NULL
)	NULL
Alain	NULL
Wargnier	NULL
$	NULL
#	NULL
§1	NULL
,	NULL
Clotilde	NULL
Lafaurie	NULL
$	NULL
§	NULL
,	NULL
Sabine	NULL
Legros-Maidaj§	NULL
,	NULL
Jean-Francois	NULL
Bourge§	NULL
,	NULL
Francois	NULL
Sigaux	NULL
$	NULL
§	NULL
,	NULL
Marilyne	NULL
Sasportes§	NULL
,	NULL
and	NULL
Pascale	NULL
Paul	NULL
!	NULL

From	NULL
§INSERM	NULL
U462	NULL
,	NULL
Institut	NULL
d'Hématologie	NULL
and	NULL
|\Service	NULL
de	NULL
Recherches	NULL
en	NULL
Hemato	NULL
Immunologie-CEA	NULL
,	NULL
Hopital	NULL
Saint-Louis	NULL
,	NULL
1	NULL
,	NULL
avenue	NULL
Claude-Vellefaux	NULL
,	NULL
75010	NULL
Paris	NULL
,	NULL
France	NULL
The	NULL
serine	NULL
protease	NULL
granzyme	NULL
B	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
granule	NULL
exocytosis	NULL
pathway	NULL
,	NULL
a	NULL
major	NULL
apoptotic	NULL
mechanism	NULL
used	NULL
by	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
and	NULL
natural	NULL
killer	NULL
cells	NULL
to	NULL
induce	NULL
target	NULL
cell	NULL
apoptosis	NULL
.	NULL

Granzyme	NULL
B	NULL
gene	NULL
transcription	NULL
is	NULL
induced	NULL
in	NULL
activated	NULL
lymphocytes	NULL
upon	NULL
antigenic	NULL
stimulation	NULL
,	NULL
and	NULL
several	NULL
regulatory	NULL
regions	NULL
including	NULL
CBF	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
Ikaros	NULL
binding	NULL
sites	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
essential	NULL
in	NULL
the	NULL
control	NULL
of	NULL
granzyme	NULL
B	NULL
promoter	NULL
activation	NULL
.	NULL

Dexamethasone	NULL
,	NULL
a	NULL
glucocorticoid	NULL
that	NULL
is	NULL
widely	NULL
used	NULL
as	NULL
an	NULL
immunomodula-tory	NULL
and	NULL
anti-inflammatory	NULL
agent	NULL
,	NULL
inhibits	NULL
granzyme	NULL
B	NULL
mRNA	NULL
transcript	NULL
in	NULL
phytohemagglutinin-activated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

Transfection	NULL
of	NULL
a	NULL
reporter	NULL
construct	NULL
containing	NULL
the	NULL
-148	NULL
to	NULL
+60	NULL
region	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
demonstrated	NULL
that	NULL
this	NULL
region	NULL
was	NULL
the	NULL
target	NULL
for	NULL
dexamethasone	NULL
repres-sion	NULL
.	NULL

Mutation	NULL
of	NULL
Ikaros	NULL
or	NULL
AP-1	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
demonstrated	NULL
that	NULL
both	NULL
sites	NULL
participate	NULL
in	NULL
dexamethasone-mediated	NULL
inhibition	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
activity	NULL
.	NULL

Electromo-bility	NULL
shift	NULL
assay	NULL
revealed	NULL
that	NULL
dexamethasone	NULL
abolished	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
and	NULL
reduced	NULL
AP-1	NULL
binding	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
dexamethasone	NULL
is	NULL
able	NULL
to	NULL
abrogate	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
gene	NULL
promoter	NULL
by	NULL
inhibiting	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
factors	NULL
at	NULL
the	NULL
AP-1	NULL
and	NULL
Ikaros	NULL
sites	NULL
.	NULL

Graft	NULL
rejection	NULL
remains	NULL
a	NULL
significant	NULL
obstacle	NULL
to	NULL
successful	NULL
allogeneic	NULL
transplantation	NULL
.	NULL

Understanding	NULL
the	NULL
molecular	NULL
mechanisms	NULL
responsible	NULL
for	NULL
allograft	NULL
rejection	NULL
is	NULL
essential	NULL
in	NULL
developing	NULL
new	NULL
therapeutic	NULL
approaches	NULL
that	NULL
will	NULL
lead	NULL
to	NULL
successful	NULL
allogeneic	NULL
transplantation	NULL
.	NULL

The	NULL
immune	NULL
effector	NULL
cells	NULL
responsible	NULL
for	NULL
this	NULL
clinical	NULL
syndrome	NULL
are	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
and	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

Antigen-triggered	NULL
T-cell	NULL
activation	NULL
induces	NULL
a	NULL
variety	NULL
of	NULL
molecular	NULL
transduction	NULL
signals	NULL
that	NULL
lead	NULL
to	NULL
the	NULL
acquisition	NULL
of	NULL
a	NULL
killing	NULL
potential	NULL
by	NULL
these	NULL
cells	NULL
.	NULL

Two	NULL
major	NULL
pathways	NULL
lead	NULL
to	NULL
the	NULL
cell	NULL
death	NULL
of	NULL
target	NULL
cells	NULL
by	NULL
cytotoxic	NULL
T	NULL
lymphocyte/granule-mediated	NULL
exocytosis	NULL
and	NULL
the	NULL
Fas/FasL	NULL
interaction	NULL
system	NULL
.	NULL

The	NULL
granule	NULL
exocytosis	NULL
pathway	NULL
is	NULL
a	NULL
major	NULL
apoptotic	NULL
mechanism	NULL
used	NULL
by	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
and	NULL
nat	NULL
*	NULL
This	NULL
work	NULL
was	NULL
funded	NULL
by	NULL
INSERM	NULL
and	NULL
the	NULL
Agence	NULL
Nationale	NULL
de	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
17834	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

J	NULL
These	NULL
two	NULL
authors	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

1	NULL
]	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Tel	NULL
:	NULL
+833158722218	NULL
;	NULL
Fax	NULL
:	NULL
+88158722217	NULL
;	NULL
E-mail	NULL
:	NULL
wargnier	NULL
@	NULL
chu-stlouis.fr	NULL
.	NULL

35326	NULL
ural	NULL
killer	NULL
cells	NULL
.	NULL

Upon	NULL
specific	NULL
recognition	NULL
and	NULL
T-cell	NULL
activation	NULL
by	NULL
foreign	NULL
antigens	NULL
present	NULL
on	NULL
target	NULL
cells	NULL
,	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
and	NULL
natural	NULL
killer	NULL
cells	NULL
accumulate	NULL
granules	NULL
in	NULL
their	NULL
cytoplasm	NULL
.	NULL

These	NULL
granules	NULL
contain	NULL
the	NULL
pore-forming	NULL
protein	NULL
perforin	NULL
,	NULL
which	NULL
undergoes	NULL
calcium-dependent	NULL
polymerization	NULL
on	NULL
the	NULL
target	NULL
cell	NULL
membrane	NULL
,	NULL
thereby	NULL
forming	NULL
a	NULL
complement-like	NULL
lesion	NULL
(	NULL
1	NULL
)	NULL
that	NULL
facilitates	NULL
delivery	NULL
of	NULL
the	NULL
granule	NULL
constituents	NULL
,	NULL
including	NULL
granzymes	NULL
,	NULL
to	NULL
the	NULL
target	NULL
cell	NULL
cytoplasm	NULL
.	NULL

Delivery	NULL
of	NULL
granule	NULL
component	NULL
proteins	NULL
is	NULL
required	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
(	NULL
2-4	NULL
)	NULL
.	NULL

Serine	NULL
protease	NULL
granzyme	NULL
B	NULL
is	NULL
an	NULL
essential	NULL
mediator	NULL
of	NULL
early	NULL
DNA	NULL
fragmentation	NULL
within	NULL
the	NULL
target	NULL
cell	NULL
in	NULL
this	NULL
pathway	NULL
(	NULL
5	NULL
)	NULL
and	NULL
elicits	NULL
apoptosis	NULL
in	NULL
target	NULL
cell	NULL
by	NULL
initiating	NULL
caspases	NULL
activation	NULL
(	NULL
6-8	NULL
)	NULL
.	NULL

Targeted	NULL
deletion	NULL
of	NULL
granzyme	NULL
B	NULL
and	NULL
perforin	NULL
genes	NULL
in	NULL
mice	NULL
also	NULL
demonstrated	NULL
their	NULL
role	NULL
in	NULL
graft	NULL
rejection	NULL
and	NULL
graft	NULL
versus	NULL
host	NULL
disease	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

In	NULL
humans	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
activated	NULL
T-cells	NULL
expressing	NULL
granzyme	NULL
B	NULL
and	NULL
perforin	NULL
has	NULL
been	NULL
observed	NULL
in	NULL
acute	NULL
heart	NULL
(	NULL
12	NULL
)	NULL
,	NULL
lung	NULL
(	NULL
13	NULL
)	NULL
,	NULL
and	NULL
kidney	NULL
allograft	NULL
rejections	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Disease	NULL
states	NULL
in	NULL
which	NULL
T-cell	NULL
and	NULL
cytokine-mediated	NULL
tissue	NULL
damage	NULL
predominate	NULL
,	NULL
including	NULL
allograft	NULL
rejection	NULL
,	NULL
autoimmune	NULL
disease	NULL
,	NULL
and	NULL
many	NULL
cases	NULL
of	NULL
chronic	NULL
inflammation	NULL
and	NULL
delayed	NULL
hypersensitivity	NULL
,	NULL
are	NULL
effectively	NULL
treated	NULL
with	NULL
glucocorticoids	NULL
.	NULL

Glucocorticoids	NULL
have	NULL
immunosuppressive	NULL
and	NULL
anti-inflammatory	NULL
properties	NULL
and	NULL
affect	NULL
the	NULL
growth	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
function	NULL
of	NULL
monocytes	NULL
and	NULL
lymphocytes	NULL
.	NULL

The	NULL
molecular	NULL
basis	NULL
of	NULL
the	NULL
immunosuppressive	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
is	NULL
still	NULL
not	NULL
clearly	NULL
understood	NULL
.	NULL

Glucocorticoids	NULL
modulate	NULL
the	NULL
production	NULL
of	NULL
various	NULL
cyto-kines	NULL
,	NULL
including	NULL
IL-1	NULL
(	NULL
16	NULL
)	NULL
,	NULL
IL-2	NULL
(	NULL
17-20	NULL
)	NULL
,	NULL
IL-4	NULL
(	NULL
21	NULL
)	NULL
,	NULL
IL-5	NULL
(	NULL
22	NULL
)	NULL
,	NULL
IL-8	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
,	NULL
interferon	NULL
y	NULL
(	NULL
17	NULL
)	NULL
,	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
(	NULL
25	NULL
)	NULL
,	NULL
and	NULL
can	NULL
exert	NULL
their	NULL
effect	NULL
by	NULL
interfering	NULL
with	NULL
the	NULL
action	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Glucocorticoids	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
repress	NULL
AP-1-mediated	NULL
transcriptional	NULL
activation	NULL
(	NULL
26	NULL
)	NULL
and	NULL
to	NULL
impair	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
27-80	NULL
)	NULL
.	NULL

NFAT	NULL
,	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T-cells	NULL
,	NULL
has	NULL
been	NULL
described	NULL
as	NULL
a	NULL
possible	NULL
target	NULL
for	NULL
dexamethasone	NULL
in	NULL
thymocyte	NULL
apoptosis	NULL
(	NULL
81	NULL
)	NULL
.	NULL

In	NULL
a	NULL
previous	NULL
study	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
granzyme	NULL
B	NULL
expression	NULL
could	NULL
be	NULL
down-regulated	NULL
at	NULL
the	NULL
protein	NULL
level	NULL
in	NULL
graft-infiltrat-ing	NULL
lymphocytes	NULL
in	NULL
heart-transplanted	NULL
patients	NULL
with	NULL
severe	NULL
and	NULL
mild	NULL
rejection	NULL
under	NULL
corticoid	NULL
treatment	NULL
(	NULL
32	NULL
)	NULL
.	NULL

This	NULL
effect	NULL
,	NULL
which	NULL
could	NULL
be	NULL
reversible	NULL
,	NULL
coincided	NULL
with	NULL
graft	NULL
stabilization	NULL
and	NULL
preceded	NULL
the	NULL
complete	NULL
disappearance	NULL
of	NULL
cellular	NULL
infiltration	NULL
(	NULL
82	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
in	NULL
kidney	NULL
transplantation	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
effective	NULL
antirejection	NULL
therapy	NULL
resulted	NULL
in	NULL
rapid	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglu-tinin	NULL
;	NULL
PBMC	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
;	NULL
Dex	NULL
,	NULL
dexamethasone	NULL
;	NULL
NF	NULL
,	NULL
nuclear	NULL
factor	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Down-regulation	NULL
of	NULL
Granzyme	NULL
B	NULL
Transcription	NULL
by	NULL
Dexamethasone	NULL
down-regulation	NULL
of	NULL
granzyme	NULL
B	NULL
,	NULL
perforin	NULL
,	NULL
and	NULL
FasL	NULL
gene	NULL
expression	NULL
(	NULL
14	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
have	NULL
examined	NULL
the	NULL
molecular	NULL
basis	NULL
of	NULL
the	NULL
previously	NULL
mentioned	NULL
down-regulation	NULL
of	NULL
lytic	NULL
protein	NULL
expression	NULL
by	NULL
glucocorticoids	NULL
.	NULL

In	NULL
both	NULL
humans	NULL
and	NULL
mice	NULL
,	NULL
the	NULL
granzyme	NULL
B	NULL
gene	NULL
is	NULL
not	NULL
expressed	NULL
in	NULL
resting	NULL
T-cells	NULL
but	NULL
is	NULL
induced	NULL
at	NULL
the	NULL
transcription	NULL
level	NULL
24	NULL
to	NULL
72	NULL
h	NULL
after	NULL
T-cell	NULL
activation	NULL
(	NULL
83	NULL
,	NULL
34	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
regulatory	NULL
element	NULL
that	NULL
controls	NULL
the	NULL
level	NULL
of	NULL
granzyme	NULL
B	NULL
gene	NULL
transcription	NULL
in	NULL
activated	NULL
T-cells	NULL
resides	NULL
between	NULL
nucleotides	NULL
-148	NULL
and	NULL
+	NULL
60	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
transcriptional	NULL
start	NULL
point	NULL
+1	NULL
)	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
gene	NULL
promoter	NULL
(	NULL
35	NULL
)	NULL
.	NULL

This	NULL
proximal	NULL
promoter	NULL
region	NULL
contains	NULL
Ikaros	NULL
and	NULL
AP-1/	NULL
CBF	NULL
binding	NULL
sites	NULL
,	NULL
previously	NULL
shown	NULL
to	NULL
be	NULL
essential	NULL
in	NULL
human	NULL
and	NULL
mouse	NULL
granzyme	NULL
B	NULL
promoter	NULL
activation	NULL
for	NULL
T-cell	NULL
stimulation	NULL
(	NULL
36-38	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
glucocorticoid	NULL
hormone	NULL
dexamethasone	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
and	NULL
DNA	NULL
binding	NULL
pattern	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
gene	NULL
promoter	NULL
in	NULL
PHA-activated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
.	NULL

We	NULL
present	NULL
evidence	NULL
that	NULL
dexamethasone	NULL
significantly	NULL
decreases	NULL
the	NULL
activation	NULL
of	NULL
granzyme	NULL
B	NULL
transcription	NULL
in	NULL
these	NULL
PHA-activated	NULL
cells	NULL
.	NULL

The	NULL
-148	NULL
to	NULL
+60	NULL
region	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
is	NULL
identified	NULL
as	NULL
a	NULL
target	NULL
for	NULL
this	NULL
suppression	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
revealed	NULL
that	NULL
dexamethasone	NULL
abolished	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
Ikaros	NULL
and	NULL
AP-1	NULL
sites	NULL
of	NULL
the	NULL
promoter	NULL
,	NULL
whereas	NULL
CBF	NULL
binding	NULL
remained	NULL
unaffected	NULL
.	NULL

We	NULL
show	NULL
here	NULL
for	NULL
the	NULL
first	NULL
time	NULL
that	NULL
dexamethasone	NULL
has	NULL
an	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
factors	NULL
to	NULL
the	NULL
Ikaros	NULL
and	NULL
AP-1	NULL
regulatory	NULL
elements	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
in	NULL
PHA-activated	NULL
PBMCs	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Cell	NULL
Culture-A	NULL
buffy	NULL
coat	NULL
of	NULL
human	NULL
PBMCs	NULL
was	NULL
purified	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
centrifugation	NULL
.	NULL

PBMCs	NULL
were	NULL
cultured	NULL
in	NULL
complete	NULL
RPMI	NULL
1640	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
inacti-vated	NULL
human	NULL
serum	NULL
and	NULL
activated	NULL
with	NULL
PHA	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
15	NULL
ug/ml	NULL
,	NULL
2	NULL
h	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
dexamethasone	NULL
at	NULL
various	NULL
concentrations	NULL
(	NULL
1	NULL
uM	NULL
,	NULL
100	NULL
nM	NULL
,	NULL
and	NULL
10	NULL
nM	NULL
)	NULL
.	NULL

RNA	NULL
Isolation	NULL
and	NULL
Northern	NULL
Blot	NULL
Hybridization-Total	NULL
cellular	NULL
RNA	NULL
was	NULL
extracted	NULL
by	NULL
immediate	NULL
solubilization	NULL
of	NULL
PBMCs	NULL
in	NULL
guanidium	NULL
isothiocyanate	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Chomezynski	NULL
and	NULL
Sacchi	NULL
(	NULL
89	NULL
)	NULL
.	NULL

After	NULL
electrophoresis	NULL
of	NULL
10	NULL
pug	NULL
of	NULL
each	NULL
RNA	NULL
through	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
formaldehyde	NULL
gel	NULL
,	NULL
transfer	NULL
to	NULL
a	NULL
Hybond	NULL
N	NULL
nitrocellulose	NULL
membrane	NULL
was	NULL
carried	NULL
out	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
.	NULL

A	NULL
granzyme	NULL
B	NULL
*°P-labeled	NULL
RNA	NULL
probe	NULL
was	NULL
prepared	NULL
using	NULL
the	NULL
sp6	NULL
RNA	NULL
polymerase	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Hybridization	NULL
was	NULL
carried	NULL
out	NULL
with	NULL
this	NULL
probe	NULL
and	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

To	NULL
verify	NULL
equal	NULL
loading	NULL
of	NULL
RNA	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
also	NULL
hybridized	NULL
with	NULL
*°P-labeled	NULL
human	NULL
B-actin	NULL
cDNA	NULL
(	NULL
CLONTECH	NULL
)	NULL
.	NULL

Construction	NULL
of	NULL
Chloramphenicol	NULL
Acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
Expression	NULL
Vectors	NULL
and	NULL
Assays-The	NULL
plasmid	NULL
PBLCAT3	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
CAT	NULL
gene	NULL
but	NULL
no	NULL
promoter	NULL
,	NULL
and	NULL
the	NULL
plasmid	NULL
PBLCAT2	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
CAT	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
,	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
G.	NULL
Schiitz	NULL
,	NULL
Heidelberg	NULL
(	NULL
41	NULL
)	NULL
.	NULL

The	NULL
CAT8A	NULL
construct	NULL
containing	NULL
the	NULL
-148	NULL
to	NULL
+60	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
85	NULL
)	NULL
.	NULL

The	NULL
wild	NULL
type	NULL
CAT2A	NULL
(	NULL
77	NULL
)	NULL
or	NULL
mutated	NULL
-148	NULL
to	NULL
-77	NULL
granzyme	NULL
B	NULL
region	NULL
CAT2AMI	NULL
(	NULL
77	NULL
)	NULL
,	NULL
CAT2AM2	NULL
(	NULL
77	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
mutations	NULL
in	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
and	NULL
the	NULL
AP-1/CBF	NULL
binding	NULL
site	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
in	NULL
the	NULL
PBLCAT2	NULL
plasmid	NULL
.	NULL

These	NULL
granzyme	NULL
B	NULL
promoter	NULL
fragments	NULL
were	NULL
obtained	NULL
by	NULL
restriction	NULL
enzyme	NULL
digestion	NULL
or	NULL
polymerase	NULL
chain	NULL
reaction	NULL
amplification	NULL
from	NULL
the	NULL
CAT3A	NULL
,	NULL
CAT8AM1	NULL
,	NULL
CATSAM2Z	NULL
vectors	NULL
previously	NULL
described	NULL
(	NULL
86	NULL
)	NULL
.	NULL

The	NULL
mutations	NULL
were	NULL
confirmed	NULL
by	NULL
dideoxy-DNA	NULL
sequencing	NULL
of	NULL
the	NULL
constructs	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
85	NULL
)	NULL
.	NULL

After	NULL
48	NULL
h	NULL
of	NULL
culture	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
using	NULL
the	NULL
Bio-Rad	NULL
gene	NULL
pulser	NULL
set	NULL
at	NULL
960	NULL
microfarads	NULL
and	NULL
250	NULL
V	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
plasmid	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
determined	NULL
24	NULL
h	NULL
later	NULL
as	NULL
described	NULL
(	NULL
85	NULL
)	NULL
and	NULL
quantified	NULL
by	NULL
liquid	NULL
scintillation	NULL
of	NULL
spots	NULL
cut	NULL
from	NULL
chromatography	NULL
plates	NULL
.	NULL

The	NULL
CDM8-Ikaros1	NULL
and	NULL
CDM8-Ikaros2	NULL
and	NULL
simian	NULL
virus	NULL
c-Jun	NULL
expression	NULL
vectors	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
K.	NULL
Georgopoulos	NULL
(	NULL
Bos-ton	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
Dr.	NULL
J.	NULL
M.	NULL
Blanchard	NULL
(	NULL
Montpellier	NULL
,	NULL
France	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Ten	NULL
ug	NULL
of	NULL
expression	NULL
vectors	NULL
were	NULL
co-transfected	NULL
by	NULL
electroporation	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Three	NULL
or	NULL
four	NULL
independent	NULL
experiments	NULL
were	NULL
per	NULL
35827	NULL
formed	NULL
in	NULL
duplicate	NULL
on	NULL
PBMCs	NULL
obtained	NULL
from	NULL
four	NULL
healthy	NULL
blood	NULL
donors	NULL
.	NULL

Oligonucleotides	NULL
and	NULL
Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay-Oligonu-cleotides	NULL
were	NULL
synthesized	NULL
on	NULL
an	NULL
Applied	NULL
Biosystems	NULL
automatic	NULL
DNA	NULL
synthesizer	NULL
and	NULL
purified	NULL
by	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

The	NULL
sequences	NULL
synthesized	NULL
(	NULL
5	NULL
'	NULL
to	NULL
3	NULL
'	NULL
)	NULL
were	NULL
:	NULL
GB1	NULL
(	NULL
-148	NULL
to	NULL
-114	NULL
)	NULL
,	NULL
TCAGGCA-GAGGCAGTGGGGGTGGGCAGCAT	NULL
;	NULL
IK	NULL
,	NULL
CATGAATGGGGGTGGCA-GAGA	NULL
;	NULL
GB2	NULL
(	NULL
-1038	NULL
to	NULL
-77	NULL
)	NULL
,	NULL
TCTGTGATGAGACACCACAAAACCAGA	NULL
;	NULL
and	NULL
AP-1	NULL
,	NULL
CGTGACTCAGCGCGG	NULL
.	NULL

All	NULL
have	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
36	NULL
)	NULL
.	NULL

GB1	NULL
is	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
.	NULL

GB2	NULL
is	NULL
the	NULL
AP-1/CBF	NULL
binding	NULL
site	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
.	NULL

IK	NULL
is	NULL
an	NULL
Ikaros	NULL
protein	NULL
binding	NULL
site	NULL
derived	NULL
from	NULL
the	NULL
mouse	NULL
CD3	NULL
8-chain	NULL
gene	NULL
enhancer	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
site	NULL
is	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
metallothionein	NULL
IIA	NULL
gene	NULL
promoter	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
86	NULL
)	NULL
48	NULL
h	NULL
after	NULL
activation	NULL
of	NULL
PBMCs	NULL
with	NULL
PHA	NULL
using	NULL
dexamethasone-treated	NULL
or	NULL
-untreated	NULL
cells	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
was	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
86	NULL
)	NULL
.	NULL

Single-stranded	NULL
oligonucleotides	NULL
were	NULL
5	NULL
'	NULL
end-labeled	NULL
with	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
annealed	NULL
with	NULL
a	NULL
2-fold	NULL
excess	NULL
of	NULL
the	NULL
unlabeled	NULL
complementary	NULL
strand	NULL
.	NULL

The	NULL
probe	NULL
was	NULL
incubated	NULL
in	NULL
a	NULL
20-ul	NULL
reaction	NULL
mix	NULL
containing	NULL
1	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
and	NULL
2	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
buffer	NULL
(	NULL
40	NULL
mM	NULL
KCl	NULL
,	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7	NULL
.	NULL

5	NULL
,	NULL
1	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.1	NULL
mM	NULL
EGTA	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
4	NULL
%	NULL
Ficoll	NULL
)	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
separated	NULL
by	NULL
5	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
revealed	NULL
by	NULL
autoradiography	NULL
.	NULL

Construction	NULL
of	NULL
Luciferase	NULL
Expression	NULL
Vector	NULL
and	NULL
Assay-Granzyme	NULL
B	NULL
promoter	NULL
fragments	NULL
were	NULL
obtained	NULL
by	NULL
restriction	NULL
enzyme	NULL
digestions	NULL
or	NULL
polymerase	NULL
chain	NULL
reaction	NULL
amplification	NULL
from	NULL
CAT8A	NULL
,	NULL
CAT8AM1	NULL
,	NULL
CATBAM2	NULL
vectors	NULL
previously	NULL
described	NULL
(	NULL
86	NULL
)	NULL
.	NULL

The	NULL
A	NULL
construct	NULL
containing	NULL
-148	NULL
to	NULL
+60	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
and	NULL
the	NULL
AM1	NULL
,	NULL
AM2	NULL
,	NULL
and	NULL
AM2A	NULL
(	NULL
mutation	NULL
within	NULL
the	NULL
GB2A	NULL
region	NULL
(	NULL
-108	NULL
to	NULL
-84	NULL
)	NULL
:	NULL
TCTTTTAT-TATACACCACAA	NULL
)	NULL
corresponding	NULL
to	NULL
mutations	NULL
in	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
,	NULL
AP-1CBF	NULL
binding	NULL
sites	NULL
,	NULL
and	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
promoterless	NULL
luciferase	NULL
reporter	NULL
gene	NULL
of	NULL
the	NULL
basic	NULL
pGL8	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
wild	NULL
type	NULL
or	NULL
mutated	NULL
-148	NULL
to	NULL
-77	NULL
granzyme	NULL
B	NULL
promoter	NULL
region	NULL
was	NULL
also	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
SV40	NULL
promoter	NULL
in	NULL
the	NULL
pGL3	NULL
promoter	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
mutations	NULL
were	NULL
confirmed	NULL
by	NULL
dideoxy-DNA	NULL
sequencing	NULL
of	NULL
the	NULL
constructs	NULL
.	NULL

After	NULL
48	NULL
h	NULL
of	NULL
culture	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
PHA-activated	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
using	NULL
4	NULL
ug	NULL
of	NULL
plasmid	NULL
.	NULL

Ten-ml	NULL
aliquots	NULL
were	NULL
measured	NULL
for	NULL
10	NULL
s	NULL
following	NULL
the	NULL
injection	NULL
of	NULL
luciferase	NULL
reagent	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
luciferase	NULL
assay	NULL
,	NULL
Promega	NULL
)	NULL
using	NULL
a	NULL
luminometer	NULL
(	NULL
Berthold	NULL
Systems	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Three	NULL
independent	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
on	NULL
PBMCs	NULL
obtained	NULL
from	NULL
three	NULL
healthy	NULL
blood	NULL
donors	NULL
.	NULL

Western	NULL
Blotting	NULL
Analysis-Twenty	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
86	NULL
)	NULL
,	NULL
and	NULL
whole	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
the	NULL
Sambrook	NULL
method	NULL
(	NULL
44	NULL
)	NULL
from	NULL
PHA-activated	NULL
PBMCs	NULL
after	NULL
48	NULL
h	NULL
of	NULL
culture	NULL
either	NULL
without	NULL
or	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
dexamethasone	NULL
(	NULL
1	NULL
uM	NULL
,	NULL
100	NULL
nM	NULL
)	NULL
and	NULL
loaded	NULL
onto	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
.	NULL

Proteins	NULL
were	NULL
blotted	NULL
onto	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
BA83	NULL
,	NULL
Sera	NULL
Labo	NULL
)	NULL
and	NULL
blocked	NULL
overnight	NULL
with	NULL
5	NULL
%	NULL
nonfat	NULL
milk/phosphate-buffered	NULL
saline	NULL
,	NULL
8	NULL
%	NULL
Tween	NULL
20	NULL
.	NULL

Membranes	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
a	NULL
1/1000	NULL
dilution	NULL
of	NULL
a	NULL
purified	NULL
anti-Ikaros	NULL
serum	NULL
(	NULL
45	NULL
)	NULL
,	NULL
then	NULL
washed	NULL
and	NULL
revealed	NULL
using	NULL
goat	NULL
anti-rabbit	NULL
IgG	NULL
peroxidase	NULL
conjugate	NULL
(	NULL
1/5000	NULL
,	NULL
1	NULL
h	NULL
)	NULL
.	NULL

Peroxidase	NULL
was	NULL
revealed	NULL
with	NULL
an	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
ECL	NULL
kit	NULL
.	NULL

Proteins	NULL
were	NULL
quantified	NULL
before	NULL
being	NULL
loaded	NULL
onto	NULL
the	NULL
gel	NULL
,	NULL
and	NULL
equal	NULL
loading	NULL
of	NULL
extracts	NULL
with	NULL
and	NULL
without	NULL
dexamethasone	NULL
was	NULL
verified	NULL
by	NULL
Ponceau	NULL
col-oration	NULL
.	NULL

Anti-Ikaros	NULL
serum	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Smale	NULL
.	NULL

Fos	NULL
proteins	NULL
were	NULL
detected	NULL
with	NULL
an	NULL
anti-Fos	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
revealed	NULL
by	NULL
an	NULL
anti-mouse	NULL
peroxidase	NULL
conjugate	NULL
(	NULL
1/2000	NULL
,	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
.	NULL

RESULTS	NULL
Dexamethasone	NULL
Partially	NULL
Abrogated	NULL
the	NULL
Stimulatory	NULL
Effect	NULL
of	NULL
PHA	NULL
on	NULL
Human	NULL
Granzyme	NULL
B	NULL
mRNA	NULL
Expression-Granzyme	NULL
B	NULL
mRNAs	NULL
expression	NULL
was	NULL
studied	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
total	NULL
RNA	NULL
samples	NULL
extracted	NULL
from	NULL
unstimulated	NULL
and	NULL
PHA-stimulated	NULL
PBMCs	NULL
.	NULL

As	NULL
expected	NULL
(	NULL
34	NULL
)	NULL
,	NULL
no	NULL
expression	NULL
was	NULL
found	NULL
in	NULL
resting	NULL
cells	NULL
,	NULL
whereas	NULL
granzyme	NULL
B	NULL
transcripts	NULL
were	NULL
detected	NULL
in	NULL
PHA-stimulated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
dexamethasone	NULL
abrogated	NULL
the	NULL
induction	NULL
of	NULL
human	NULL
granzyme	NULL
B	NULL
messenger	NULL
RNA	NULL
expression	NULL
,	NULL
which	NULL
was	NULL
observed	NULL
after	NULL
PHA	NULL
stimulation	NULL
of	NULL
PBMCs	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

CD8*	NULL
T	NULL
lymphocytes	NULL
,	NULL
which	NULL
expressed	NULL
a	NULL
higher	NULL
granzyme	NULL
B	NULL
level	NULL
than	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
,	NULL
are	NULL
highly	NULL
sensitive	NULL
to	NULL
dexamethasone-induced	NULL
apoptosis	NULL
(	NULL
46	NULL
)	NULL
.	NULL

To	NULL
elimi-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
353828	NULL
PHA	NULL
_-	NULL
+	NULL
+	NULL
Dex	NULL
_	NULL
-	NULL
=	NULL
+	NULL
granzyme	NULL
B	NULL
actin	NULL
.	NULL

>	NULL
-	NULL
came	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Inhibition	NULL
of	NULL
granzyme	NULL
B	NULL
RNA	NULL
expression	NULL
by	NULL
Dex	NULL
.	NULL

Total	NULL
RNA	NULL
from	NULL
resting	NULL
PBMCs	NULL
,	NULL
PHA-stimulated	NULL
PBMCs	NULL
,	NULL
and	NULL
PHA-stimulated	NULL
PBMCs	NULL
treated	NULL
with	NULL
1	NULL
uM	NULL
of	NULL
Dex	NULL
were	NULL
successively	NULL
hybridized	NULL
with	NULL
a	NULL
granzyme	NULL
B	NULL
riboprobe	NULL
(	NULL
see	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
)	NULL
and	NULL
B	NULL
actin	NULL
cDNA	NULL
.	NULL

nate	NULL
the	NULL
possibility	NULL
of	NULL
dexamethasone-induced	NULL
down-regulation	NULL
of	NULL
granzyme	NULL
B	NULL
transcription	NULL
because	NULL
of	NULL
apoptosis	NULL
of	NULL
CD8*	NULL
cells	NULL
,	NULL
the	NULL
CD4*/CD8*	NULL
ratio	NULL
before	NULL
and	NULL
after	NULL
dexamethasone	NULL
treatment	NULL
was	NULL
analyzed	NULL
by	NULL
cytofluorometry	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
this	NULL
ratio	NULL
could	NULL
be	NULL
demonstrated	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

PHA	NULL
Activation	NULL
of	NULL
the	NULL
Granzyme	NULL
B	NULL
Promoter	NULL
Was	NULL
Down-regulated	NULL
by	NULL
Dexamethasone	NULL
in	NULL
Primary	NULL
Human	NULL
PBMCs-To	NULL
determine	NULL
whether	NULL
one	NULL
of	NULL
the	NULL
possible	NULL
mechanisms	NULL
of	NULL
dexamethasone	NULL
inhibition	NULL
of	NULL
granzyme	NULL
B	NULL
mRNA	NULL
induction	NULL
involved	NULL
a	NULL
change	NULL
in	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
,	NULL
we	NULL
transiently	NULL
transfected	NULL
PHA-activated	NULL
PBMCs	NULL
with	NULL
a	NULL
vector	NULL
in	NULL
which	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
transcription	NULL
was	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
gene	NULL
proximal	NULL
promoter	NULL
(	NULL
-148	NULL
to	NULL
+	NULL
60	NULL
)	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

The	NULL
CAT	NULL
activity	NULL
driven	NULL
by	NULL
the	NULL
reporter	NULL
fragment	NULL
was	NULL
significantly	NULL
inhibited	NULL
by	NULL
treatment	NULL
with	NULL
three	NULL
different	NULL
concentrations	NULL
of	NULL
dexamethasone	NULL
(	NULL
1	NULL
uM	NULL
,	NULL
100	NULL
nm	NULL
,	NULL
and	NULL
10	NULL
nx	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Dexamethasone	NULL
was	NULL
thus	NULL
found	NULL
to	NULL
inhibit	NULL
granzyme	NULL
B	NULL
promoter	NULL
activation	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

Binding	NULL
of	NULL
Nuclear	NULL
Proteins	NULL
from	NULL
Stimulated	NULL
Primary	NULL
Human	NULL
PBMCs	NULL
to	NULL
the	NULL
Ikaros	NULL
GBI	NULL
and	NULL
AP-1	NULL
GB2	NULL
Sites	NULL
of	NULL
the	NULL
Granzyme	NULL
B	NULL
Promoter	NULL
was	NULL
Inhibited	NULL
by	NULL
Dexamethasone-We	NULL
investigated	NULL
whether	NULL
dexamethasone	NULL
inhibited	NULL
granzyme	NULL
B	NULL
gene	NULL
transcription	NULL
by	NULL
interfering	NULL
with	NULL
nuclear	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
GB1	NULL
(	NULL
-143	NULL
to	NULL
-114	NULL
)	NULL
and	NULL
the	NULL
AP-1/CBF	NULL
binding	NULL
site	NULL
GB2	NULL
(	NULL
-103	NULL
to	NULL
-77	NULL
)	NULL
were	NULL
essential	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
in	NULL
PHA-stimulated	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
PHA-stimulated	NULL
PBMCs	NULL
were	NULL
analyzed	NULL
by	NULL
mobility	NULL
shift	NULL
assays	NULL
with	NULL
GB1	NULL
and	NULL
GB2	NULL
probes	NULL
,	NULL
and	NULL
the	NULL
consensus	NULL
Ikaros	NULL
binding	NULL
site	NULL
was	NULL
derived	NULL
from	NULL
the	NULL
mouse	NULL
CD3	NULL
8-chain	NULL
gene	NULL
enhancer	NULL
(	NULL
42	NULL
)	NULL
.	NULL

These	NULL
results	NULL
revealed	NULL
that	NULL
dexamethasone	NULL
inhibited	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
Ikaros	NULL
GB1	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
as	NULL
well	NULL
as	NULL
to	NULL
the	NULL
consensus	NULL
Ikaros	NULL
binding	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
IK	NULL
)	NULL
and	NULL
reduced	NULL
AP-1	NULL
binding	NULL
activity	NULL
,	NULL
whereas	NULL
CBF	NULL
binding	NULL
activity	NULL
to	NULL
the	NULL
GB2	NULL
site	NULL
remained	NULL
unaffected	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Both	NULL
Ikaros	NULL
and	NULL
AP-1	NULL
Binding	NULL
Sites	NULL
Participate	NULL
in	NULL
Dexamethasone-mediated	NULL
Inhibition	NULL
of	NULL
Granzyme	NULL
B	NULL
Promoter	NULL
Activ-ity-Two	NULL
binding	NULL
sites	NULL
,	NULL
the	NULL
Ikaros	NULL
and	NULL
AP-1/CBF	NULL
binding	NULL
sites	NULL
,	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
granzyme	NULL
B	NULL
promoter	NULL
activation	NULL
(	NULL
36-38	NULL
)	NULL
.	NULL

To	NULL
further	NULL
evaluate	NULL
the	NULL
contribution	NULL
of	NULL
these	NULL
sites	NULL
to	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
,	NULL
we	NULL
introduced	NULL
mutations	NULL
able	NULL
to	NULL
selectively	NULL
abolish	NULL
binding	NULL
of	NULL
complexes	NULL
to	NULL
the	NULL
Ikaros	NULL
,	NULL
AP-1	NULL
,	NULL
or	NULL
AP-1/CBF	NULL
sites	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
(	NULL
36	NULL
)	NULL
.	NULL

To	NULL
gain	NULL
sensibility	NULL
in	NULL
this	NULL
analysis	NULL
,	NULL
these	NULL
granzyme	NULL
B	NULL
promoter	NULL
constructs	NULL
were	NULL
introduced	NULL
in	NULL
a	NULL
luciferase	NULL
promoterless	NULL
reporter	NULL
construct	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
in	NULL
PHA-stimulated	NULL
PBMCs	NULL
was	NULL
significantly	NULL
inhibited	NULL
by	NULL
dexamethasone	NULL
.	NULL

Mutations	NULL
that	NULL
Down-regulation	NULL
of	NULL
Granzyme	NULL
B	NULL
Transcription	NULL
by	NULL
Dexamethasone	NULL
BACAT3	NULL
@	NULL
cCaT3A	NULL
100	NULL
50	NULL
relative	NULL
CAT	NULL
activity	NULL
10	NULL
0	NULL
0	NULL
0.01	NULL
0.1	NULL
1	NULL
Dexamethasone	NULL
(	NULL
M	NULL
)	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Dexamethasone	NULL
inhibits	NULL
the	NULL
PHA-mediated	NULL
transacti-vation	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
.	NULL

PBMCs	NULL
were	NULL
activated	NULL
with	NULL
PHA	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
15	NULL
ug/ml	NULL
with	NULL
or	NULL
without	NULL
Dex	NULL
at	NULL
different	NULL
concentrations	NULL
(	NULL
1	NULL
uM	NULL
,	NULL
100	NULL
nM	NULL
,	NULL
and	NULL
10	NULL
nM	NULL
)	NULL
.	NULL

After	NULL
48	NULL
h	NULL
of	NULL
culture	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
plasmid	NULL
CATS8A	NULL
or	NULL
PBLCAT3	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
assayed	NULL
24	NULL
h	NULL
later	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
activation	NULL
relative	NULL
to	NULL
the	NULL
CATSA	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dexamethasone	NULL
(	NULL
taken	NULL
as	NULL
100	NULL
%	NULL
)	NULL
represents	NULL
the	NULL
mean	NULL
values	NULL
+S.E	NULL
.	NULL

of	NULL
at	NULL
least	NULL
four	NULL
individual	NULL
experiments	NULL
in	NULL
duplicate	NULL
.	NULL

The	NULL
CAT38	NULL
is	NULL
vector	NULL
without	NULL
promoter	NULL
.	NULL

abolished	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
nuclear	NULL
factors	NULL
on	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
partially	NULL
reduced	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
activity	NULL
in	NULL
PHA-activated	NULL
cells	NULL
,	NULL
but	NULL
treatment	NULL
with	NULL
dexamethasone	NULL
was	NULL
still	NULL
able	NULL
to	NULL
modulate	NULL
the	NULL
residual	NULL
luciferase	NULL
activity	NULL
driven	NULL
by	NULL
the	NULL
Ikaros-mutated	NULL
promoter	NULL
fragment	NULL
.	NULL

This	NULL
result	NULL
is	NULL
in	NULL
favor	NULL
of	NULL
a	NULL
role	NULL
for	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
in	NULL
dexamethasone-mediated	NULL
inhibition	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
AP-1/CBF	NULL
binding	NULL
site	NULL
or	NULL
selective	NULL
mutations	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
also	NULL
reduced	NULL
the	NULL
level	NULL
of	NULL
granzyme	NULL
B	NULL
promoter	NULL
activity	NULL
in	NULL
PHA-activated	NULL
cells	NULL
.	NULL

An	NULL
inhibitory	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
mutated	NULL
promoter	NULL
containing	NULL
an	NULL
intact	NULL
Ikaros	NULL
binding	NULL
site	NULL
was	NULL
still	NULL
ob-served	NULL
,	NULL
confirming	NULL
the	NULL
role	NULL
of	NULL
the	NULL
Ikaros	NULL
regulatory	NULL
element	NULL
in	NULL
dexamethasone-mediated	NULL
inhibition	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
insertion	NULL
of	NULL
a	NULL
limited	NULL
region	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
(	NULL
-148	NULL
to	NULL
-77	NULL
)	NULL
,	NULL
which	NULL
only	NULL
contains	NULL
wild	NULL
type	NULL
or	NULL
mutated	NULL
Ikaros	NULL
and	NULL
AP-1/CBF	NULL
binding	NULL
sites	NULL
upstream	NULL
of	NULL
the	NULL
SV40	NULL
promoter	NULL
in	NULL
the	NULL
pGL3	NULL
vector	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Altogether	NULL
these	NULL
data	NULL
show	NULL
that	NULL
the	NULL
two	NULL
DNA	NULL
binding	NULL
sites	NULL
,	NULL
Ikaros	NULL
and	NULL
AP-1	NULL
,	NULL
both	NULL
represent	NULL
critical	NULL
regulatory	NULL
targets	NULL
for	NULL
dexamethasone-induced	NULL
down-regulation	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
.	NULL

Considering	NULL
the	NULL
critical	NULL
role	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
cotransfection	NULL
of	NULL
a	NULL
c-Jun	NULL
expression	NULL
vector	NULL
on	NULL
the	NULL
dexamethasone-mediated	NULL
inhibition	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
cotransfection	NULL
of	NULL
c-Jun	NULL
expression	NULL
vector	NULL
partially	NULL
restores	NULL
PHA	NULL
activation	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
in	NULL
presence	NULL
of	NULL
dexamethasone	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
cotransfection	NULL
experiment	NULL
with	NULL
c-Jun	NULL
can	NULL
not	NULL
reverse	NULL
glucocorti-coid-mediated	NULL
repression	NULL
of	NULL
CAT2AM2	NULL
(	NULL
77	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
mutation	NULL
on	NULL
the	NULL
AP-1/CBF	NULL
binding	NULL
site	NULL
with	NULL
an	NULL
intact	NULL
Ikaros	NULL
binding	NULL
site	NULL
but	NULL
is	NULL
very	NULL
potent	NULL
at	NULL
reversing	NULL
repression	NULL
of	NULL
CAT2AMI	NULL
(	NULL
77	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
mutation	NULL
in	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
with	NULL
an	NULL
intact	NULL
AP-1/CBF	NULL
binding	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
c-Jun	NULL
cotransfection	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
activity	NULL
.	NULL

The	NULL
Dex	NULL
treatment	NULL
and	NULL
the	NULL
c-Jun	NULL
cotransfection	NULL
have	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
PBLCAT2	NULL
vector	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
potential	NULL
candidate	NULL
proteins	NULL
that	NULL
could	NULL
interact	NULL
with	NULL
the	NULL
granzyme	NULL
B	NULL
Ikaros	NULL
regulatory	NULL
element	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
Ikaros	NULL
protein	NULL
expression	NULL
in	NULL
PHA-activated	NULL
PBMCs	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
revealed	NULL
that	NULL
dexamethasone	NULL
treatment	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
moderate	NULL
decrease	NULL
of	NULL
the	NULL
bands	NULL
whose	NULL
size	NULL
correspond	NULL
to	NULL
Ik1	NULL
and	NULL
Ik2/3	NULL
isoforms	NULL
(	NULL
45	NULL
,	NULL
47	NULL
,	NULL
48	NULL
)	NULL
and	NULL
apparition	NULL
of	NULL
a	NULL
band	NULL
with	NULL
a	NULL
smaller	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Down-regulation	NULL
of	NULL
Granzyme	NULL
B	NULL
Transcription	NULL
by	NULL
Dexamethasone	NULL
PHA	NULL
4+	NULL
+0	NULL
4+	NULL
++	NULL
Dex	NULL
_	NULL
10nM	NULL
100nM	NULL
.L	NULL
_	NULL
Competitor	NULL
.	NULL

se	NULL
-	NULL
GB1	NULL
UR	NULL
soi	NULL
B	NULL
PHA	NULL
+	NULL
+	NULL
+	NULL
[	NULL
+	NULL
+	NULL
Dex	NULL
_	NULL
10nM	NULL
100nM	NULL
.	NULL

m	NULL
Competitor	NULL
_.	NULL
s	NULL
=	NULL
IK	NULL
_	NULL
UR	NULL
-	NULL
»	NULL
|	NULL
#	NULL
66	NULL
ln	NULL
1	NULL
20	NULL
3	NULL
4	NULL
5	NULL
FiG	NULL
.	NULL

3	NULL
.	NULL

A	NULL
,	NULL
dexamethasone	NULL
inhibits	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
PHA-stimulated	NULL
PBMCs	NULL
to	NULL
the	NULL
Ikaros	NULL
GB1	NULL
site	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
.	NULL

A	NULL
*°P-end-labeled	NULL
GB1	NULL
probe	NULL
that	NULL
includes	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
PHA-stimulated	NULL
PBMCs	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Dex	NULL
at	NULL
various	NULL
concentrations	NULL
(	NULL
see	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
)	NULL
.	NULL

Complexes	NULL
whose	NULL
formations	NULL
are	NULL
inhibited	NULL
by	NULL
Dex	NULL
are	NULL
indicated	NULL
.	NULL

Binding	NULL
specificity	NULL
was	NULL
attributed	NULL
using	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
GB1	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
and	NULL
unrelated	NULL
(	NULL
UR	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
unlabeled	NULL
competitors	NULL
.	NULL

B	NULL
,	NULL
dexamethasone	NULL
inhibits	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
PHA-stimulated	NULL
PBMCs	NULL
to	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
CD3-5	NULL
enhancer	NULL
.	NULL

A	NULL
*°P-end-labeled	NULL
IK	NULL
probe	NULL
including	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
CD3-8	NULL
enhancer	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
PHA-stimulated	NULL
PBMCs	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Dex	NULL
at	NULL
different	NULL
concentrations	NULL
(	NULL
see	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
)	NULL
.	NULL

Complexes	NULL
whose	NULL
formations	NULL
are	NULL
inhibited	NULL
by	NULL
Dex	NULL
are	NULL
indicated	NULL
.	NULL

Specificity	NULL
of	NULL
binding	NULL
was	NULL
attributed	NULL
using	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
IK	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
and	NULL
unrelated	NULL
(	NULL
UR	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
unlabeled	NULL
competitors	NULL
.	NULL

size	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
Ikaros	NULL
proteins	NULL
was	NULL
unchanged	NULL
by	NULL
the	NULL
dexamethasone	NULL
treatment	NULL
in	NULL
whole	NULL
extracts	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
dexamethasone	NULL
modulates	NULL
protein	NULL
nuclear	NULL
expression	NULL
of	NULL
Ikaros	NULL
isoforms	NULL
.	NULL

However	NULL
,	NULL
cotransfection	NULL
experiments	NULL
with	NULL
Ik1	NULL
and	NULL
Ik2	NULL
expression	NULL
vectors	NULL
(	NULL
47	NULL
)	NULL
did	NULL
not	NULL
restore	NULL
activity	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
in	NULL
dexamethasone-treated	NULL
PHA	NULL
PBMCs	NULL
(	NULL
data	NULL
not	NULL
35329	NULL
PHA	NULL
_	NULL
4	NULL
4	NULL
+	NULL
#	NULL
Dex	NULL
_	NULL
-	NULL
-	NULL
+	NULL
=	NULL
AP1	NULL
competitor	NULL
-	NULL
-	NULL
_-	NULL
>	NULL
AP1	NULL
-|	NULL
@	NULL
R	NULL
car	NULL
>	NULL
|	NULL
Chk	NULL
#	NULL
#	NULL
#	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Dexamethasone	NULL
inhibits	NULL
AP-1	NULL
binding	NULL
activity	NULL
but	NULL
does	NULL
not	NULL
affect	NULL
CBF	NULL
binding	NULL
activity	NULL
to	NULL
the	NULL
AP-1/CBF	NULL
GB2	NULL
site	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
PHA-stimulated	NULL
PBMCs	NULL
.	NULL

A	NULL
*	NULL
``	NULL
P-end-labeled	NULL
GB2	NULL
probe	NULL
that	NULL
includes	NULL
the	NULL
AP-1/CBF	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
PHA-stimulated	NULL
PBMCs	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Dex	NULL
(	NULL
see	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
)	NULL
.	NULL

AP-1-and	NULL
CBF-related	NULL
complexes	NULL
are	NULL
indicated	NULL
and	NULL
have	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
86	NULL
)	NULL
.	NULL

shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
overexpression	NULL
of	NULL
these	NULL
isoforms	NULL
per	NULL
se	NULL
is	NULL
not	NULL
able	NULL
to	NULL
counterbalance	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
dexamethasone	NULL
.	NULL

DISCUSSION	NULL
Although	NULL
glucocorticoids	NULL
are	NULL
among	NULL
the	NULL
most	NULL
potent	NULL
and	NULL
widely	NULL
used	NULL
immunosuppressive	NULL
agents	NULL
,	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
they	NULL
suppress	NULL
the	NULL
immune	NULL
response	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
clearly	NULL
defined	NULL
.	NULL

Glucocorticoids	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
able	NULL
to	NULL
affect	NULL
monocyte	NULL
and	NULL
T	NULL
lymphocyte	NULL
proliferation	NULL
and	NULL
function	NULL
(	NULL
49-51	NULL
)	NULL
.	NULL

The	NULL
main	NULL
mechanism	NULL
by	NULL
which	NULL
they	NULL
exert	NULL
their	NULL
powerful	NULL
effects	NULL
is	NULL
modulation	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
specific	NULL
sets	NULL
of	NULL
genes	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Glucocorticoids	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
cytokine	NULL
expression	NULL
at	NULL
both	NULL
the	NULL
transcriptional	NULL
and	NULL
post-transcriptional	NULL
levels	NULL
.	NULL

Recently	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
its	NULL
distal	NULL
effect	NULL
on	NULL
gene	NULL
expression	NULL
,	NULL
dexamethasone	NULL
has	NULL
been	NULL
described	NULL
as	NULL
down-regulating	NULL
T-cell	NULL
activation	NULL
by	NULL
inhibiting	NULL
the	NULL
transduction	NULL
of	NULL
activation	NULL
signals	NULL
initiated	NULL
upon	NULL
T-cell	NULL
receptor	NULL
occupancy	NULL
(	NULL
52	NULL
)	NULL
and	NULL
IL-2	NULL
receptor	NULL
(	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
IL-2	NULL
and	NULL
interferon	NULL
y	NULL
gene	NULL
expression	NULL
,	NULL
which	NULL
are	NULL
early	NULL
events	NULL
in	NULL
T-cell	NULL
activation	NULL
,	NULL
induction	NULL
of	NULL
granzyme	NULL
B	NULL
gene	NULL
transcription	NULL
is	NULL
a	NULL
late-phase	NULL
event	NULL
that	NULL
characterizes	NULL
the	NULL
acquisition	NULL
of	NULL
the	NULL
cytotoxic	NULL
function	NULL
by	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
results	NULL
of	NULL
this	NULL
study	NULL
demonstrated	NULL
that	NULL
inhibition	NULL
of	NULL
late-phase	NULL
granzyme	NULL
B	NULL
gene	NULL
expression	NULL
by	NULL
glucocorticoids	NULL
occurred	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
concentration-dependent	NULL
inhibition	NULL
of	NULL
granzyme	NULL
B	NULL
gene	NULL
promoter	NULL
activity	NULL
.	NULL

Glucocorticoids	NULL
exert	NULL
their	NULL
effects	NULL
after	NULL
diffusing	NULL
into	NULL
target	NULL
cells	NULL
,	NULL
where	NULL
they	NULL
bind	NULL
to	NULL
their	NULL
cytoplasmic	NULL
receptor	NULL
.	NULL

This	NULL
complex	NULL
then	NULL
translocates	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
where	NULL
it	NULL
inhibits	NULL
the	NULL
transcription	NULL
of	NULL
target	NULL
genes	NULL
.	NULL

This	NULL
inhibition	NULL
can	NULL
occur	NULL
through	NULL
direct	NULL
binding	NULL
to	NULL
the	NULL
glucocorticoid	NULL
response	NULL
elements	NULL
,	NULL
located	NULL
within	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
genes	NULL
(	NULL
55	NULL
)	NULL
.	NULL

No	NULL
differential	NULL
DNA	NULL
binding	NULL
activity	NULL
to	NULL
putative	NULL
glucocorticoid	NULL
receptor	NULL
element	NULL
sites	NULL
identified	NULL
within	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
by	NULL
sequence	NULL
homologies	NULL
to	NULL
glucocorticoid	NULL
receptor	NULL
element	NULL
consensus	NULL
sequences	NULL
could	NULL
be	NULL
detected	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Other	NULL
mechanisms	NULL
of	NULL
glucocorticoid	NULL
suppressive	NULL
effects	NULL
that	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
35330	NULL
[	NULL
J	NULL
Dex	NULL
1	NULL
uM	NULL
gg	NULL
Dex	NULL
0.1	NULL
uM	NULL
I	NULL
no	NULL
Dex	NULL
PGL3AMA	NULL
|	NULL
14s	NULL
-o+Gfo-	NULL
E	NULL
PGL3AM2	NULL
-	NULL
14	NULL
-O-	NULL
[	NULL
E	NULL
PGL3AM1	NULL
_	NULL
14	NULL
-B§Co-PGL3A	NULL
IK	NULL
APLCBF	NULL
=	NULL
200	NULL
600	NULL
1000	NULL
1600	NULL
luciferase	NULL
activity	NULL
[	NULL
Q	NULL
]	NULL
CAT3A	NULL
+	NULL
SV	NULL
c-Jun	NULL
CAT3A	NULL
Dex	NULL
1uM	NULL
F	NULL
I	NULL
Dex	NULL
0.1	NULL
uM	NULL
no	NULL
Dex	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
70	NULL
so	NULL
90	NULL
100	NULL
CAT	NULL
relative	NULL
activity	NULL
O0	NULL
Dex	NULL
0,1	NULL
uM	NULL
+	NULL
SV	NULL
c-Jun	NULL
EH	NULL
Dex	NULL
0.1	NULL
uM	NULL
H	NULL
no	NULL
Dex	NULL
CAT2AM2	NULL
(	NULL
77	NULL
)	NULL
CAT2AM1	NULL
(	NULL
77	NULL
)	NULL
CAT2A	NULL
(	NULL
77	NULL
)	NULL
i	NULL
;	NULL
2	NULL
‘	NULL
0	NULL
4.0	NULL
8.0	NULL
80	NULL
100	NULL
CAT	NULL
relative	NULL
activity	NULL
FiG	NULL
.	NULL

5	NULL
.	NULL

A	NULL
,	NULL
both	NULL
Ikaros	NULL
and	NULL
AP-1	NULL
are	NULL
involved	NULL
in	NULL
dexamethasone-induced	NULL
down-regulation	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
.	NULL

PHA-activated	NULL
PBMCs	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Dex	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
(	NULL
A	NULL
)	NULL
,	NULL
-148	NULL
to	NULL
+60	NULL
granzyme	NULL
B	NULL
promoter	NULL
,	NULL
and	NULL
mutated	NULL
promoter	NULL
constructs	NULL
AM1	NULL
(	NULL
mutated	NULL
Ikaros	NULL
binding	NULL
site	NULL
)	NULL
,	NULL
AM2	NULL
(	NULL
AP-1/CBF	NULL
mutated	NULL
binding	NULL
site	NULL
)	NULL
,	NULL
and	NULL
AM2A	NULL
(	NULL
mutated	NULL
AP-1	NULL
binding	NULL
site	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
was	NULL
performed	NULL
three	NULL
times	NULL
in	NULL
duplicate	NULL
with	NULL
similar	NULL
results	NULL
and	NULL
bars	NULL
represent	NULL
the	NULL
S.D	NULL
.	NULL

values	NULL
.	NULL

B	NULL
,	NULL
c-Jun	NULL
overexpression	NULL
restores	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
activity	NULL
in	NULL
presence	NULL
of	NULL
dexamethasone	NULL
.	NULL

PBMCs	NULL
were	NULL
activated	NULL
with	NULL
PHA	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
15	NULL
ug/ml	NULL
with	NULL
or	NULL
without	NULL
Dex	NULL
at	NULL
different	NULL
concentrations	NULL
(	NULL
1	NULL
uM	NULL
and	NULL
100	NULL
nM	NULL
)	NULL
.	NULL

After	NULL
48	NULL
h	NULL
of	NULL
culture	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
plasmid	NULL
CATSA	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
simian	NULL
virus	NULL
c-Jun	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
assayed	NULL
24	NULL
h	NULL
later	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
activation	NULL
relative	NULL
to	NULL
the	NULL
CATSA	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dexamethasone	NULL
(	NULL
taken	NULL
as	NULL
100	NULL
%	NULL
)	NULL
represents	NULL
the	NULL
mean	NULL
value	NULL
+8.E	NULL
.	NULL

of	NULL
three	NULL
individual	NULL
experiments	NULL
in	NULL
duplicate	NULL
.	NULL

CAT3	NULL
is	NULL
a	NULL
promoterless	NULL
vector	NULL
.	NULL

C	NULL
,	NULL
c-Jun	NULL
overexpression	NULL
restores	NULL
the	NULL
AP-1/CBF	NULL
binding	NULL
site	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
Ikaros	NULL
binding	NULL
site	NULL
activity	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
promoter	NULL
.	NULL

PHA-activated	NULL
PBMCs	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Dex	NULL
were	NULL
cotransfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
A	NULL
(	NULL
77	NULL
)	NULL
-148	NULL
to	NULL
-77	NULL
granzyme	NULL
B	NULL
promoter	NULL
and	NULL
mutated	NULL
promoter	NULL
construct	NULL
AM1	NULL
(	NULL
77	NULL
)	NULL
(	NULL
mutated	NULL
Ikaros	NULL
binding	NULL
site	NULL
)	NULL
,	NULL
AM2	NULL
(	NULL
77	NULL
)	NULL
(	NULL
AP-1/CBF	NULL
mutated	NULL
binding	NULL
site	NULL
)	NULL
,	NULL
and	NULL
10	NULL
pg	NULL
of	NULL
simian	NULL
virus	NULL
c-Jun	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
activation	NULL
relative	NULL
to	NULL
the	NULL
CAT2A	NULL
(	NULL
77	NULL
)	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dexamethasone	NULL
(	NULL
taken	NULL
as	NULL
100	NULL
%	NULL
)	NULL
represents	NULL
the	NULL
mean	NULL
value	NULL
+8.E	NULL
.	NULL

of	NULL
three	NULL
individual	NULL
experiments	NULL
in	NULL
duplicate	NULL
.	NULL

Down-regulation	NULL
of	NULL
Granzyme	NULL
B	NULL
Transcription	NULL
by	NULL
Dexamethasone	NULL
PHA	NULL
+o	NULL
++	NULL
$	NULL
Dex	NULL
1uM	NULL
100nM	NULL
-_	NULL
3	NULL
IK1	NULL
_	NULL
-m	NULL
am	NULL
comi	NULL
.	NULL

aa	NULL
-	NULL
64	NULL
Kda	NULL
Ik2/3	NULL
--	NULL
Win	NULL
-	NULL
waitin	NULL
-	NULL
WW	NULL
E	NULL
-	NULL
52	NULL
Kda	NULL
-t	NULL
»	NULL
-	NULL
39	NULL
Kda	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Dexamethasone	NULL
modulates	NULL
expression	NULL
of	NULL
Ikaros	NULL
isoforms	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

PHA-stimulated	NULL
PBMCs	NULL
were	NULL
cultured	NULL
with	NULL
different	NULL
doses	NULL
of	NULL
Dex	NULL
(	NULL
see	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blot	NULL
using	NULL
anti-Ikaros	NULL
antiserum	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
various	NULL
Ikaros	NULL
isoforms	NULL
are	NULL
indicated	NULL
.	NULL

involve	NULL
antagonism	NULL
of	NULL
the	NULL
action	NULL
of	NULL
transcription	NULL
factors	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
have	NULL
been	NULL
described	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
the	NULL
consequence	NULL
of	NULL
negative	NULL
interference	NULL
with	NULL
AP-1	NULL
and	NULL
NFAT	NULL
(	NULL
nucle-ar	NULL
factor	NULL
of	NULL
activated	NULL
T-cells	NULL
)	NULL
nuclear	NULL
transcriptional	NULL
factors	NULL
,	NULL
which	NULL
have	NULL
been	NULL
previously	NULL
demonstrated	NULL
to	NULL
be	NULL
of	NULL
crucial	NULL
importance	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
cytokine	NULL
promoter	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Although	NULL
AP-1	NULL
is	NULL
involved	NULL
in	NULL
lymphokine	NULL
gene	NULL
induction	NULL
,	NULL
interference	NULL
with	NULL
AP-1	NULL
activity	NULL
can	NULL
not	NULL
account	NULL
for	NULL
the	NULL
full	NULL
spectrum	NULL
of	NULL
immunoregulatory	NULL
genes	NULL
affected	NULL
by	NULL
glucocorticoids	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
glucocorticoids	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
by	NULL
increasing	NULL
transcription	NULL
and	NULL
protein	NULL
synthesis	NULL
of	NULL
its	NULL
cytoplasmic	NULL
inhibitor	NULL
IxBa	NULL
(	NULL
27	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
dexamethasone	NULL
represses	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
nuclear	NULL
NF-kB	NULL
(	NULL
28	NULL
,	NULL
30	NULL
)	NULL
.	NULL

Glucocorticoid	NULL
suppression	NULL
of	NULL
a	NULL
member	NULL
of	NULL
the	NULL
rat	NULL
IL-8	NULL
family	NULL
is	NULL
also	NULL
mediated	NULL
by	NULL
impairment	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
24	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
dexamethasone	NULL
inhibits	NULL
granzyme	NULL
B	NULL
gene	NULL
promoter	NULL
activity	NULL
induction	NULL
by	NULL
interfering	NULL
with	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
Ikaros	NULL
GBI	NULL
site	NULL
and	NULL
by	NULL
reducing	NULL
the	NULL
amount	NULL
of	NULL
AP-1	NULL
binding	NULL
activity	NULL
while	NULL
not	NULL
affecting	NULL
CBF	NULL
binding	NULL
activity	NULL
to	NULL
the	NULL
GB2	NULL
site	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
AP-1	NULL
is	NULL
inhibited	NULL
by	NULL
glucocorticoids	NULL
is	NULL
well	NULL
documented	NULL
and	NULL
implicates	NULL
interaction	NULL
between	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
and	NULL
Jun	NULL
and	NULL
Fos	NULL
,	NULL
the	NULL
two	NULL
proteins	NULL
that	NULL
transactivate	NULL
transcription	NULL
when	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
(	NULL
26	NULL
,	NULL
56-59	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
in	NULL
our	NULL
model	NULL
,	NULL
Fos	NULL
protein	NULL
nuclear	NULL
expression	NULL
is	NULL
not	NULL
down-regulated	NULL
by	NULL
dexamethasone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
an	NULL
Ikaros	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
dexamethasone-mediated	NULL
inhibition	NULL
of	NULL
gene	NULL
transcription	NULL
has	NULL
not	NULL
yet	NULL
been	NULL
described	NULL
.	NULL

Candidate	NULL
proteins	NULL
that	NULL
could	NULL
bind	NULL
the	NULL
granzyme	NULL
B	NULL
Ikaros	NULL
site	NULL
are	NULL
the	NULL
different	NULL
isoforms	NULL
(	NULL
Ik1	NULL
,	NULL
2	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
6	NULL
)	NULL
encoded	NULL
by	NULL
the	NULL
Ikaros	NULL
gene	NULL
(	NULL
45	NULL
,	NULL
47	NULL
,	NULL
48	NULL
)	NULL
,	NULL
an	NULL
essential	NULL
regulator	NULL
of	NULL
lymphocyte	NULL
differentiation	NULL
(	NULL
42	NULL
,	NULL
60	NULL
)	NULL
.	NULL

Ikaros	NULL
activity	NULL
is	NULL
controlled	NULL
by	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
complexes	NULL
formed	NULL
between	NULL
its	NULL
expressed	NULL
isoforms	NULL
(	NULL
61	NULL
)	NULL
.	NULL

Homo-	NULL
and	NULL
heterodimer	NULL
formation	NULL
between	NULL
the	NULL
DNA-binding	NULL
Ikaros	NULL
isoforms	NULL
(	NULL
Ik1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
3	NULL
)	NULL
greatly	NULL
increases	NULL
their	NULL
affinity	NULL
for	NULL
DNA	NULL
and	NULL
their	NULL
consequent	NULL
ability	NULL
to	NULL
activate	NULL
transcription	NULL
.	NULL

Heterodimers	NULL
formed	NULL
between	NULL
isoforms	NULL
Ik1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
3	NULL
with	NULL
Ik4	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
lead	NULL
to	NULL
transcriptionally	NULL
inactive	NULL
forms	NULL
(	NULL
61	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
heterodimers	NULL
that	NULL
include	NULL
one	NULL
Ikaros	NULL
isoform	NULL
that	NULL
lacks	NULL
a	NULL
DNA	NULL
binding	NULL
domain	NULL
are	NULL
transcriptionally	NULL
inert	NULL
.	NULL

The	NULL
observation	NULL
of	NULL
a	NULL
new	NULL
band	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
using	NULL
the	NULL
anti-Ikaros	NULL
antibody	NULL
with	NULL
nuclear	NULL
extracts	NULL
upon	NULL
dexamethasone	NULL
treatment	NULL
is	NULL
compatible	NULL
with	NULL
the	NULL
expression	NULL
of	NULL
such	NULL
an	NULL
isoform	NULL
lacking	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
.	NULL

As	NULL
recently	NULL
sug-gested	NULL
,	NULL
such	NULL
isoforms	NULL
could	NULL
interfere	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
Ikaros	NULL
or	NULL
Ikaros-like	NULL
binding	NULL
factors	NULL
such	NULL
as	NULL
Aiolos	NULL
,	NULL
Helios	NULL
,	NULL
p30	NULL
(	NULL
62	NULL
,	NULL
63	NULL
)	NULL
,	NULL
or	NULL
other	NULL
yet-undefined	NULL
partners	NULL
in	NULL
a	NULL
dominant	NULL
negative	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Down-regulation	NULL
of	NULL
Granzyme	NULL
B	NULL
Transcription	NULL
by	NULL
Dexamethasone	NULL
fashion	NULL
.	NULL

Dexamethasone	NULL
treatment	NULL
could	NULL
generate	NULL
the	NULL
presence	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
isoform	NULL
.	NULL

This	NULL
interpretation	NULL
is	NULL
compatible	NULL
with	NULL
the	NULL
absence	NULL
of	NULL
retarded	NULL
bound	NULL
complexes	NULL
in	NULL
bandshift	NULL
assay	NULL
.	NULL

Morever	NULL
,	NULL
our	NULL
preliminary	NULL
results	NULL
are	NULL
not	NULL
in	NULL
favor	NULL
of	NULL
an	NULL
enhancement	NULL
of	NULL
granzyme	NULL
B	NULL
promoter	NULL
activity	NULL
consecutive	NULL
to	NULL
independent	NULL
cotransfection	NULL
of	NULL
recombi-nant	NULL
Ik1	NULL
and	NULL
Ik2	NULL
isoforms	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
other	NULL
lineage-specific	NULL
partners	NULL
may	NULL
interact	NULL
with	NULL
the	NULL
granzyme	NULL
B	NULL
Ikaros	NULL
regulatory	NULL
element	NULL
.	NULL

Further	NULL
analyses	NULL
are	NULL
necessary	NULL
to	NULL
elucidate	NULL
dexamethasone	NULL
inhibition	NULL
mechanisms	NULL
involving	NULL
the	NULL
Ikaros	NULL
regulatory	NULL
element	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
Ikaros	NULL
and	NULL
AP-1	NULL
binding	NULL
sites	NULL
of	NULL
the	NULL
human	NULL
granzyme	NULL
B	NULL
promoter	NULL
are	NULL
both	NULL
critical	NULL
for	NULL
the	NULL
dexamethasone-induced	NULL
down-regulation	NULL
of	NULL
the	NULL
granzyme	NULL
B	NULL
gene	NULL
expression	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Dr.	NULL
Katia	NULL
Georgopoulos	NULL
,	NULL
Dr.	NULL
Stephen	NULL
Smale	NULL
,	NULL
and	NULL
Dr.	NULL
Jean-Marie	NULL
Blanchard	NULL
for	NULL
generously	NULL
donating	NULL
re-agents	NULL
.	NULL

We	NULL
are	NULL
extremely	NULL
grateful	NULL
to	NULL
Helene	NULL
Dastot	NULL
and	NULL
Xavier	NULL
Fund	NULL
for	NULL
technical	NULL
support	NULL
,	NULL
Dr.	NULL
Marc-Henri	NULL
Stern	NULL
and	NULL
Dr.	NULL
Michel	NULL
Raymondjean	NULL
for	NULL
helpful	NULL
discussion	NULL
and	NULL
Noah	NULL
Hardy	NULL
for	NULL
reading	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Podack	NULL
,	NULL
E.	NULL
,	NULL
Young	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Cohn	NULL
,	NULL
Z	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

82	NULL
,	NULL
8629-8633	NULL
2	NULL
.	NULL

Shi	NULL
,	NULL
L.	NULL
,	NULL
Kam	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Powers	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Aebersold	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Greenberg	NULL
,	NULL
A.	NULL
H.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176	NULL
,	NULL
1521-1529	NULL
3	NULL
.	NULL

Nakajima	NULL
,	NULL
H.	NULL
,	NULL
Park	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
and	NULL
Henkart	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
1037-1046	NULL
4	NULL
.	NULL

Shiver	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Su	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Henkart	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
71	NULL
,	NULL
815-322	NULL
5	NULL
.	NULL

Heusel	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Wesselschmidt	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Shresta	NULL
,	NULL
S.	NULL
,	NULL
Russell	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Ley	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
977-987	NULL
6	NULL
.	NULL

Darmon	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Ley	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Nicholson	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
and	NULL
Bleackley	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
21709-21712	NULL
7	NULL
.	NULL

Quan	NULL
,	NULL
L.	NULL
T.	NULL
,	NULL
Tewari	NULL
,	NULL
M.	NULL
,	NULL
O'Rourke	NULL
,	NULL
K.	NULL
,	NULL
Dixit	NULL
,	NULL
V.	NULL
,	NULL
Snipas	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Poirier	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
Ray	NULL
,	NULL
C.	NULL
,	NULL
Pickup	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
and	NULL
Salvesen	NULL
,	NULL
G.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

NaH	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
1972-1976	NULL
8	NULL
.	NULL

Talanian	NULL
,	NULL
R.	NULL
V.	NULL
,	NULL
Yang	NULL
,	NULL
X.	NULL
H.	NULL
,	NULL
Turbov	NULL
,	NULL
J.	NULL
,	NULL
Seth	NULL
,	NULL
P.	NULL
,	NULL
Gbayur	NULL
,	NULL
T.	NULL
,	NULL
Casiano	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Orth	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Froelich	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186	NULL
,	NULL
1323-1331	NULL
9	NULL
.	NULL

Schulz	NULL
,	NULL
M.	NULL
,	NULL
Schuurman	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Joergensen	NULL
,	NULL
J.	NULL
,	NULL
Steiner	NULL
,	NULL
C.	NULL
,	NULL
Meerloo	NULL
,	NULL
T.	NULL
,	NULL
Kigi	NULL
,	NULL
D.	NULL
,	NULL
Hentgartner	NULL
,	NULL
H.	NULL
,	NULL
Zinkernagel	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Schreier	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Biirki	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Lederman	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25	NULL
,	NULL
474-480	NULL
10	NULL
.	NULL

Graubert	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Russell	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Ley	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Blood	NULL
87	NULL
,	NULL
1232-1237	NULL
11	NULL
.	NULL

Graubert	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
DiPersio	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Russell	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Ley	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

100	NULL
,	NULL
904-911	NULL
12	NULL
.	NULL

Clement	NULL
,	NULL
M.	NULL
V.	NULL
,	NULL
Haddad	NULL
,	NULL
P.	NULL
,	NULL
Soulie	NULL
,	NULL
A.	NULL
,	NULL
Benvenuti	NULL
,	NULL
C.	NULL
,	NULL
Lichtenheld	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Podack	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
Sigaux	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Sasportes	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Inf	NULL
.	NULL

Immunol	NULL
.	NULL

3	NULL
,	NULL
1175-1181	NULL
13	NULL
.	NULL

Clement	NULL
,	NULL
M.	NULL
V.	NULL
,	NULL
Legros-Maida	NULL
,	NULL
S.	NULL
,	NULL
Israel-Biet	NULL
,	NULL
D.	NULL
,	NULL
Carnot	NULL
,	NULL
F.	NULL
,	NULL
Soulie	NULL
,	NULL
A.	NULL
,	NULL
Rey-naud	NULL
,	NULL
P.	NULL
,	NULL
Guillet	NULL
,	NULL
J.	NULL
,	NULL
Gandjbakch	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Sasportes	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Transplantation	NULL
57	NULL
,	NULL
822-826	NULL
14	NULL
.	NULL

Strehlau	NULL
,	NULL
J.	NULL
,	NULL
Pavlakis	NULL
,	NULL
M.	NULL
,	NULL
Lipman	NULL
,	NULL
M.	NULL
,	NULL
Shapiro	NULL
,	NULL
M.	NULL
,	NULL
Vasconcellos	NULL
,	NULL
L.	NULL
,	NULL
Har-mons	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Strom	NULL
,	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

94	NULL
,	NULL
695-700	NULL
15	NULL
.	NULL

Clement	NULL
,	NULL
M.	NULL
V.	NULL
,	NULL
Haddad	NULL
,	NULL
P.	NULL
,	NULL
Ring	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
Pruna	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Sasportes	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Hum	NULL
.	NULL

Immunol	NULL
.	NULL

28	NULL
,	NULL
159-166	NULL
16	NULL
.	NULL

Lee	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Tsou	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
Chan	NULL
,	NULL
H.	NULL
,	NULL
Thomas	NULL
,	NULL
J.	NULL
,	NULL
Petrie	NULL
,	NULL
K.	NULL
,	NULL
Eugui	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
and	NULL
Allison	NULL
,	NULL
A.	NULL
C.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

85	NULL
,	NULL
1204-1208	NULL
17	NULL
.	NULL

Arya	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Wong-Staal	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1984	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

188	NULL
,	NULL
273-276	NULL
18	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
Raptis	NULL
,	NULL
A.	NULL
,	NULL
Ahuja	NULL
,	NULL
S.	NULL
,	NULL
Najjar	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Boumpas	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

91	NULL
,	NULL
1481-1489	NULL
19	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
,	NULL
Felli	NULL
,	NULL
M.	NULL
,	NULL
Farina	NULL
,	NULL
A.	NULL
,	NULL
Martinotti	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Maroder	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
637-646	NULL
20	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Mattila	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
1285-1245	NULL
21	NULL
.	NULL

Wu	NULL
,	NULL
CY	NULL
.	NULL

,	NULL
Fargeas	NULL
,	NULL
C.	NULL
,	NULL
Nakajima	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Delespesse	NULL
,	NULL
G.	NULL
(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

21	NULL
,	NULL
2645-2647	NULL
22	NULL
.	NULL

Mori	NULL
,	NULL
A.	NULL
,	NULL
Kaminuma	NULL
,	NULL
O.	NULL
,	NULL
Suko	NULL
,	NULL
M.	NULL
,	NULL
Inoue	NULL
,	NULL
S.	NULL
,	NULL
Ohmura	NULL
,	NULL
T.	NULL
,	NULL
Hoshino	NULL
,	NULL
A.	NULL
,	NULL
Asakura	NULL
,	NULL
Y.	NULL
,	NULL
Miyazawa	NULL
,	NULL
K.	NULL
,	NULL
Yokota	NULL
,	NULL
T.	NULL
,	NULL
Okumura	NULL
,	NULL
Y.	NULL
,	NULL
Ito	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Okudaira	NULL
,	NULL
H.	NULL
(	NULL
1997	NULL
)	NULL
Blood	NULL
89	NULL
,	NULL
2891-2900	NULL
28	NULL
.	NULL

Mukaida	NULL
,	NULL
N.	NULL
,	NULL
Gussela	NULL
G.	NULL
L.	NULL
,	NULL
Kasahara	NULL
T.	NULL
,	NULL
Zachariae	NULL
C.	NULL
O.	NULL
,	NULL
Kawai	NULL
T.	NULL
,	NULL
and	NULL
Matsushima	NULL
,	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
Immunology	NULL
75	NULL
,	NULL
674-679	NULL
35331	NULL
24	NULL
.	NULL

Ohtsuka	NULL
,	NULL
T.	NULL
,	NULL
Kubota	NULL
,	NULL
A.	NULL
,	NULL
Hirano	NULL
,	NULL
T.	NULL
,	NULL
Watanabe	NULL
,	NULL
K.	NULL
,	NULL
Yoshida	NULL
,	NULL
H.	NULL
,	NULL
Tsurufuji	NULL
,	NULL
M.	NULL
,	NULL
Tizuka	NULL
,	NULL
Y.	NULL
,	NULL
Konishi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Tsurufuji	NULL
,	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
1651-1659	NULL
25	NULL
.	NULL

Beutler	NULL
,	NULL
B.	NULL
,	NULL
Krochin	NULL
,	NULL
N.	NULL
,	NULL
Milsark	NULL
,	NULL
I.	NULL
W.	NULL
,	NULL
Luedke	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Cerami	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Science	NULL
282	NULL
,	NULL
977-980	NULL
26	NULL
.	NULL

Jonat	NULL
,	NULL
C.	NULL
,	NULL
Rahmsdorf	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Park	NULL
,	NULL
K.	NULL
K.	NULL
,	NULL
Cato	NULL
,	NULL
A.	NULL
C.	NULL
B.	NULL
,	NULL
Gebel	NULL
,	NULL
S.	NULL
,	NULL
Ponta	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Herrlich	NULL
,	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
62	NULL
,	NULL
1189-1204	NULL
27	NULL
.	NULL

Scheinman	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Cogswell	NULL
,	NULL
P.	NULL
C.	NULL
,	NULL
Lofquist	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Jr.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
270	NULL
,	NULL
283-286	NULL
28	NULL
.	NULL

Scheinman	NULL
,	NULL
R.	NULL
I.	NULL
,	NULL
Gualberto	NULL
,	NULL
A.	NULL
,	NULL
Jewell	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Cidlowski	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Jr.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
948-953	NULL
29	NULL
.	NULL

Auphan	NULL
,	NULL
N.	NULL
,	NULL
DiDonato	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Rosette	NULL
,	NULL
C.	NULL
,	NULL
Helmberg	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
270	NULL
,	NULL
286-290	NULL
30	NULL
.	NULL

Ray	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Prefontaine	NULL
,	NULL
K.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

91	NULL
,	NULL
752-1756	NULL
31	NULL
.	NULL

Wisniewska	NULL
,	NULL
M.	NULL
,	NULL
Stanczyk	NULL
,	NULL
M.	NULL
,	NULL
Grzelakowska-Sztabert	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Kaminska	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Cell	NULL
Biol	NULL
.	NULL

Int	NULL
.	NULL

21	NULL
,	NULL
127-132	NULL
82	NULL
.	NULL

Legros-Maida	NULL
,	NULL
S.	NULL
,	NULL
Soulié	NULL
,	NULL
A.	NULL
,	NULL
Benvenuti	NULL
,	NULL
C.	NULL
,	NULL
Wargnier	NULL
,	NULL
A.	NULL
,	NULL
Vallée	NULL
,	NULL
N.	NULL
,	NULL
Berthou	NULL
,	NULL
C.	NULL
,	NULL
Guillet	NULL
,	NULL
J.	NULL
,	NULL
Sasportes	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Sigaux	NULL
,	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24	NULL
,	NULL
229-233	NULL
33	NULL
.	NULL

Caputo	NULL
,	NULL
A.	NULL
,	NULL
Fahey	NULL
,	NULL
D.	NULL
,	NULL
Lloyd	NULL
,	NULL
C.	NULL
,	NULL
Vozab	NULL
,	NULL
R.	NULL
,	NULL
McCairns	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Rowe	NULL
,	NULL
P.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
6363-6369	NULL
34	NULL
.	NULL

Heusel	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Hanson	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Silverman	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
and	NULL
Ley	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
6152-6158	NULL
35	NULL
.	NULL

Haddad	NULL
,	NULL
P.	NULL
,	NULL
Wargnier	NULL
,	NULL
A.	NULL
,	NULL
Bourge	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Sasportes	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Paul	NULL
,	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28	NULL
,	NULL
625-629	NULL
36	NULL
.	NULL

Wargnier	NULL
,	NULL
A.	NULL
,	NULL
Legros-Maida	NULL
,	NULL
S.	NULL
,	NULL
Bosselut	NULL
,	NULL
R.	NULL
,	NULL
Bourge	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Lafauric	NULL
,	NULL
C.	NULL
,	NULL
Ghysdael	NULL
,	NULL
J.	NULL
,	NULL
Sasportes	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Paul	NULL
,	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

92	NULL
,	NULL
6930-6934	NULL
37	NULL
.	NULL

Babichuk	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
Duggan	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
and	NULL
Bleackley	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
16485-16498	NULL
38	NULL
.	NULL

Babichuk	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
and	NULL
Bleackley	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
18564-18571	NULL
39	NULL
.	NULL

Chomezynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Sacchi	NULL
,	NULL
N.	NULL
(	NULL
1987	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162	NULL
,	NULL
156-159	NULL
40	NULL
.	NULL

Clement	NULL
,	NULL
V.	NULL
,	NULL
Haddad	NULL
,	NULL
P.	NULL
,	NULL
Soulie	NULL
,	NULL
A.	NULL
,	NULL
Legros-Maida	NULL
,	NULL
S.	NULL
,	NULL
Guillet	NULL
,	NULL
J.	NULL
,	NULL
Cesar	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Sasportes	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Res	NULL
.	NULL

Immunol	NULL
.	NULL

141	NULL
,	NULL
477-489	NULL
41	NULL
.	NULL

Luckow	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Schutz	NULL
,	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15	NULL
,	NULL
5490	NULL
42	NULL
.	NULL

Georgopoulos	NULL
,	NULL
K.	NULL
,	NULL
Moore	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
and	NULL
Derfler	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
258	NULL
,	NULL
808-812	NULL
43	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Imbra	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Rahmsdorf	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Jonat	NULL
,	NULL
C.	NULL
,	NULL
Herrlich	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
729-739	NULL
44	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
and	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
,	NULL
2nd	NULL
Ed	NULL
.	NULL

,	NULL
pp	NULL
.	NULL

16.66-16.67	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Labo-ratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
45	NULL
.	NULL

Hahm	NULL
,	NULL
K.	NULL
,	NULL
Ernst	NULL
,	NULL
P.	NULL
,	NULL
Lo	NULL
,	NULL
K.	NULL
,	NULL
Kim	NULL
,	NULL
G.	NULL
,	NULL
Turck	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Smale	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
7111-7123	NULL
46	NULL
.	NULL

Lanza	NULL
,	NULL
L.	NULL
,	NULL
Scudeletti	NULL
,	NULL
M.	NULL
,	NULL
Puppo	NULL
,	NULL
F.	NULL
,	NULL
Bosco	NULL
,	NULL
O.	NULL
,	NULL
Peirano	NULL
,	NULL
L.	NULL
,	NULL
Filaci	NULL
,	NULL
G.	NULL
,	NULL
Fe-carotta	NULL
,	NULL
E.	NULL
,	NULL
Vidali	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Indiveri	NULL
,	NULL
F.	NULL
(	NULL
1996	NULL
)	NULL
Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

103	NULL
,	NULL
482-490	NULL
47	NULL
.	NULL

Molnar	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Georgopoulos	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
8292-8303	NULL
48	NULL
.	NULL

Molnar	NULL
,	NULL
A.	NULL
,	NULL
Wu	NULL
,	NULL
P.	NULL
,	NULL
Largespada	NULL
,	NULL
D.	NULL
,	NULL
Vortkamp	NULL
,	NULL
A.	NULL
,	NULL
Scherer	NULL
,	NULL
S.	NULL
,	NULL
Copeland	NULL
,	NULL
N.	NULL
,	NULL
Jenkins	NULL
,	NULL
N.	NULL
,	NULL
Bruns	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Georgopoulos	NULL
,	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
585-592	NULL
49	NULL
.	NULL

Boumpas	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
Anastassiou	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
and	NULL
Balow	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
Clin	NULL
.	NULL

Exp	NULL
.	NULL

Rheumatol	NULL
.	NULL

9	NULL
,	NULL
413-423	NULL
50	NULL
.	NULL

Gillis	NULL
,	NULL
S.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

128	NULL
,	NULL
1624-1631	NULL
51	NULL
.	NULL

Gillis	NULL
,	NULL
S.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

128	NULL
,	NULL
1632-1638	NULL
52	NULL
.	NULL

Baus	NULL
,	NULL
E.	NULL
,	NULL
Andris	NULL
,	NULL
F.	NULL
,	NULL
Dubois	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Urbain	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Leo	NULL
,	NULL
O	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
4555-4561	NULL
53	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
Abuja	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Ballow	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Balow	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
and	NULL
Boumpas	NULL
,	NULL
D.	NULL
T.	NULL
(	NULL
19938	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
4081-4089	NULL
54	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
Hama	NULL
,	NULL
N.	NULL
,	NULL
Balow	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Valentine	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Boumpas	NULL
D.	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

155	NULL
,	NULL
1809-1817	NULL
55	NULL
.	NULL

Drouin	NULL
,	NULL
J	NULL
.	NULL

(	NULL
19983	NULL
)	NULL
in	NULL
Frontiers	NULL
in	NULL
Molecular	NULL
Biology	NULL
:	NULL
Steroid	NULL
Action	NULL
(	NULL
Parker	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
ed	NULL
)	NULL
pp	NULL
.	NULL

118-140	NULL
,	NULL
Oxford	NULL
University	NULL
Press	NULL
,	NULL
Oxford	NULL
56	NULL
.	NULL

Miner	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
and	NULL
Yamamoto	NULL
,	NULL
K.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

6	NULL
,	NULL
2491-2501	NULL
57	NULL
.	NULL

Yang-yen	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
Chambard	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Sun	NULL
,	NULL
Y.	NULL
L.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Schmidt	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Drouin	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
62	NULL
,	NULL
1205-1215	NULL
58	NULL
.	NULL

Lucibello	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
Slater	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Jooss	NULL
,	NULL
K.	NULL
U.	NULL
,	NULL
Beato	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Muller	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
2827-2834	NULL
59	NULL
.	NULL

Schule	NULL
,	NULL
R.	NULL
,	NULL
Ranganajan	NULL
,	NULL
P.	NULL
,	NULL
Kliewev	NULL
,	NULL
S.	NULL
,	NULL
Ransome	NULL
,	NULL
L.	NULL
,	NULL
Bolado	NULL
,	NULL
J.	NULL
,	NULL
Yang	NULL
,	NULL
N.	NULL
,	NULL
Verna	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
62	NULL
,	NULL
1217-1226	NULL
60	NULL
.	NULL

Georgopoulos	NULL
,	NULL
K.	NULL
,	NULL
Bigby	NULL
,	NULL
M.	NULL
,	NULL
Wang	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Molnar	NULL
,	NULL
A.	NULL
,	NULL
Wu	NULL
,	NULL
P.	NULL
,	NULL
Winandy	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Sharpe	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
79	NULL
,	NULL
148-156	NULL
61	NULL
.	NULL

Sun	NULL
,	NULL
L.	NULL
,	NULL
Liu	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Georgopoulos	NULL
,	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

15	NULL
,	NULL
5358-5369	NULL
62	NULL
.	NULL

Morgan	NULL
,	NULL
B.	NULL
,	NULL
Sun	NULL
,	NULL
L.	NULL
,	NULL
Avitahl	NULL
,	NULL
N.	NULL
,	NULL
Andrikopoulos	NULL
,	NULL
K.	NULL
,	NULL
Ikeda	NULL
,	NULL
T.	NULL
,	NULL
Gonzales	NULL
,	NULL
H.	NULL
,	NULL
Wu	NULL
,	NULL
P.	NULL
,	NULL
Neben	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Georgopoulos	NULL
,	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

16	NULL
,	NULL
2004-2018	NULL
63	NULL
.	NULL

Hahm	NULL
,	NULL
K.	NULL
,	NULL
Cobb	NULL
,	NULL
B.	NULL
,	NULL
McCarty	NULL
,	NULL
A.	NULL
,	NULL
Brown	NULL
,	NULL
K.	NULL
,	NULL
Klug	NULL
,	NULL
C.	NULL
,	NULL
Lee	NULL
,	NULL
R.	NULL
,	NULL
Akashi	NULL
,	NULL
K.	NULL
,	NULL
Weissman	NULL
,	NULL
I.	NULL
,	NULL
Fisher	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Smale	NULL
,	NULL
S.	NULL
(	NULL
1998	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

12	NULL
,	NULL
782-796	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Down-regulation	NULL
of	NULL
Human	NULL
Granzyme	NULL
B	NULL
Expression	NULL
by	NULL
Glucocorticoids	NULL
:	NULL
DEXAMETHASONE	NULL
INHIBITS	NULL
BINDING	NULL
TO	NULL
THE	NULL
Ikaros	NULL
AND	NULL
AP-1	NULL
REGULATORY	NULL
ELEMENTS	NULL
OF	NULL
THE	NULL
GRANZYME	NULL
B	NULL
PROMOTER	NULL
Alain	NULL
Wargnier	NULL
,	NULL
Clotilde	NULL
Lafaurie	NULL
,	NULL
Sabine	NULL
Legros-Mai	NULL
?	NULL

da	NULL
,	NULL
Jean-Francois	NULL
Bourge	NULL
,	NULL
Frangois	NULL
Sigaux	NULL
,	NULL
Marilyne	NULL
Sasportes	NULL
and	NULL
Pascale	NULL
Paul	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1998	NULL
,	NULL
273:35326-35331.	NULL
doi	NULL
:	NULL
10.1074/jb0.273.52.35326	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/273/52/35326	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
61	NULL
references	NULL
,	NULL
36	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

